Metformin Medicare Part D Coverage: What You Pay in 2025-2026

Why Metformin Is the Easiest Diabetes Drug to Cover

Metformin sits on nearly every Part D formulary in the country because it is off-patent, inexpensive to manufacture, and recommended as first-line therapy by every major diabetes guideline. The American Diabetes Association (ADA) 2024 Standards of Care names metformin the preferred initial pharmacologic agent for most adults with type 2 diabetes, citing its efficacy, safety profile, low cost, and decades of outcome data [1]. That guideline status effectively guarantees formulary inclusion.

Generic metformin hydrochloride tablets have been available in the United States since 2002. The FDA's Orange Book lists dozens of approved generic manufacturers [2]. This level of competition keeps the average wholesale price below $0.10 per tablet for the 500 mg and 850 mg immediate-release strengths. For Part D plan sponsors, including metformin as a Tier 1 preferred generic is a straightforward decision: the drug is cheap, broadly indicated, and clinically supported by trials enrolling tens of thousands of patients.

The Diabetes Prevention Program (DPP) trial (N=3,234) demonstrated that metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% compared to placebo over 2.8 years of follow-up [3]. A 15-year extension of that trial confirmed durable risk reduction [4]. These large, well-powered results are part of why the CDC estimates that over 37 million Americans live with diabetes and metformin remains the most prescribed antihyperglycemic agent in the country [5].

How Part D Formulary Tiers Work for Metformin

Part D plans organize covered drugs into tiers, and your copay depends on which tier a drug occupies. Generic metformin almost always lands on Tier 1, the lowest-cost tier.

Here is the typical tier structure across Medicare Part D plans:

Tier 1 (Preferred Generic): $0 to $15 copay. This is where immediate-release and most extended-release metformin formulations sit. Some Medicare Advantage plans with Part D (MA-PD) offer $0 copays for Tier 1 generics as a plan benefit enhancement.

Tier 2 (Generic): $5 to $25 copay. A small number of plans place certain extended-release formulations here, particularly branded generics or specific ER matrix tablets.

Tier 3 (Preferred Brand): $30 to $50 copay. Brand-name Glucophage or Glucophage XR could land here, though most physicians prescribe generic.

According to a 2023 analysis published in JAMA Internal Medicine, generic drugs on Tier 1 of Part D formularies had a median copay of $3 per 30-day fill [6]. Metformin, as one of the highest-volume generics dispensed, consistently falls at or below that median. The Centers for Medicare & Medicaid Services (CMS) requires all Part D sponsors to cover "all or substantially all" drugs in six protected classes; while antidiabetics are not a protected class, the sheer clinical necessity and low cost of metformin means plan exclusion is virtually unheard of.

A 2024 KFF analysis reported that 89% of Part D standalone plans listed metformin immediate-release with a $0 copay during the initial coverage phase [7]. Extended-release formulations showed slightly more variation, with copays ranging from $0 to $12 depending on the specific plan and the ER technology (osmotic vs. matrix).

The 2025 Part D Redesign: The $2,000 Out-of-Pocket Cap

The Inflation Reduction Act (IRA), signed in August 2022, restructured Medicare Part D cost-sharing in phases. The most consequential change took effect January 1, 2025: a hard $2,000 annual cap on out-of-pocket spending for all Part D covered drugs [8].

For metformin users specifically, the $2,000 cap provides peace of mind but rarely changes monthly spending. A beneficiary filling metformin 1,000 mg twice daily (a standard dose) at a $5 copay accumulates roughly $60 per year in out-of-pocket costs for that single medication. The cap matters more if metformin is part of a larger regimen that includes costlier drugs like SGLT2 inhibitors or GLP-1 receptor agonists.

The IRA also introduced the Medicare Prescription Payment Plan (M3P) starting in 2025, which allows beneficiaries to spread their out-of-pocket costs across monthly installments rather than paying large sums at the pharmacy counter [8]. For patients on multiple medications whose combined annual cost approaches the $2,000 cap, M3P can reduce the month-to-month financial burden significantly.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, noted in a 2024 statement: "The $2,000 cap represents the most significant reduction in prescription drug costs for Medicare beneficiaries in the program's history. For patients managing diabetes with multiple medications, this change can mean hundreds of dollars in annual savings" [9].

Extra Help, Low-Income Subsidy, and State Pharmaceutical Assistance

Medicare's Extra Help program (also called the Low-Income Subsidy, or LIS) covers a portion or all of Part D premiums, deductibles, and copays for beneficiaries with limited income and resources. As of 2025, beneficiaries who qualify for full Extra Help pay no more than $4.50 for generic drugs like metformin per prescription [10].

Eligibility thresholds for 2025 are approximately:

• Full LIS: Income below 135% of the federal poverty level (roughly $20,783 for an individual) and resources below $17,220.
• Partial LIS: Income below 150% of the federal poverty level (roughly $23,092 for an individual) and resources below $17,220.

Full LIS beneficiaries who fill metformin typically pay $0 to $2.15 per prescription. Partial LIS beneficiaries pay a sliding-scale copay, but for a Tier 1 generic, costs remain minimal.

State Pharmaceutical Assistance Programs (SPAPs) provide additional coverage in about 20 states. Programs vary widely. New York's EPIC program, for example, covers Part D cost-sharing for residents aged 65+ with incomes up to $75,000 (single) or $100,000 (married) [11]. Pennsylvania's PACE/PACENET serves a similar role. Beneficiaries enrolled in both an SPAP and Part D may pay nothing out of pocket for metformin.

The Social Security Administration processes Extra Help applications. The ADA has recommended that clinicians routinely screen patients for LIS eligibility, as the National Council on Aging estimated in 2023 that approximately 3.2 million Medicare beneficiaries eligible for Extra Help were not enrolled [12].

Brand-Name vs. Generic Metformin: What Part D Covers and What It Costs More

Generic metformin hydrochloride tablets are therapeutically equivalent to brand-name Glucophage. The FDA rates them as AB-rated substitutes, meaning pharmacies can (and routinely do) automatically substitute the generic unless the prescriber writes "dispense as written" [2].

Brand-name options that still exist include:

• Glucophage / Glucophage XR: The original brand. Rarely dispensed in brand form. If a plan covers it, expect a Tier 3 copay ($30 to $50).
• Glumetza: An extended-release formulation using a gastric-retentive technology. Has faced pricing controversies. A Federal Trade Commission investigation into Glumetza's pricing led to a 2024 settlement with the manufacturer [13]. When covered, Glumetza typically sits on Tier 3 or requires prior authorization.
• Riomet / Riomet ER: Liquid metformin formulation for patients who cannot swallow tablets. More expensive (cash price around $200 to $500 per month). Part D plans may cover it on Tier 3 or Tier 4 with a prior authorization requiring documentation of swallowing difficulty.

For the vast majority of patients, generic metformin (immediate-release or extended-release) provides identical clinical benefit at a fraction of the cost. The 2024 ADA Standards of Care does not differentiate between brand and generic metformin in its treatment algorithms [1].

One clinical note on extended-release formulations: in 2020, the FDA issued recalls for certain ER metformin products due to NDMA (N-Nitrosodimethylamine) contamination above acceptable intake limits [14]. Those specific lots have been removed from the market, and current generic ER metformin products meet FDA safety standards. Patients or caregivers concerned about past recalls should verify their current prescription with their pharmacist.

How to Get Metformin for Less Than Your Part D Copay

This sounds counterintuitive, but some beneficiaries pay less by not using their Part D benefit for metformin. Cash-pay pricing at major pharmacies can undercut Part D copays.

Walmart, Costco, and several grocery-store pharmacies offer metformin 500 mg and 850 mg immediate-release tablets for $4 per 30-day supply or $10 per 90-day supply through their generic discount programs. These prices require no insurance, no coupon, and no membership (Costco pharmacy is accessible to non-members by federal law).

Discount platforms like GoodRx and RxSaver display real-time pricing across local pharmacies. A spot check in May 2026 shows metformin 500 mg #60 (a typical 30-day supply at 1,000 mg/day) priced between $3.50 and $9.00 at most national chains.

Mark Cuban Cost Plus Drugs offers metformin 500 mg #60 at a cash price of approximately $4.20 including shipping, with transparent markup disclosed on their website.

Important: If you fill metformin outside of Part D (using cash or a discount card), that spending does not count toward your Part D deductible or the $2,000 out-of-pocket cap. For patients whose total annual drug spending is well below the cap, this is irrelevant. For patients on expensive combination regimens, it may be strategically better to fill metformin through Part D so that even the small copay counts toward reaching the cap.

Dr. Stacie Dusetzina, Professor of Health Policy at Vanderbilt University Medical Center, has written: "Patients should compare their plan copay against cash prices at the pharmacy counter. For high-volume generics like metformin, cash pricing is sometimes lower than the negotiated Part D copay, but beneficiaries need to understand the tradeoff with their annual out-of-pocket accumulator" [15].

Metformin for Off-Label Uses: Does Part D Still Pay?

Metformin's FDA-approved indication is type 2 diabetes mellitus [2]. Part D plans are not required to cover off-label uses unless the use is supported by one of the recognized drug compendia (such as the AHFS Drug Information compendium or Micromedex DrugDex).

Common off-label uses for metformin include:

• Prediabetes / diabetes prevention: Supported by the DPP trial, which showed a 31% reduction in diabetes incidence [3]. The ADA recommends considering metformin for prediabetes prevention in patients with BMI ≥35, those under age 60, or women with prior gestational diabetes [1]. Many Part D plans cover this use when the prescriber documents a prediabetes diagnosis (ICD-10 R73.03).
• Polycystic ovary syndrome (PCOS): The American College of Obstetricians and Gynecologists (ACOG) recognizes metformin as a treatment option for PCOS-related metabolic dysfunction [16]. Coverage depends on the plan, but a prediabetes or insulin-resistance diagnosis code generally facilitates approval.
• Weight management (adjunctive): Not a standard indication. Coverage is unlikely without a diabetes or prediabetes diagnosis.
• Longevity / anti-aging: The TAME (Targeting Aging with Metformin) trial is underway, but no results are published yet, and no Part D plan covers metformin for this purpose [17].

If your prescriber writes metformin for an off-label use and the pharmacy rejects the claim, ask the prescriber to submit a coverage determination request with supporting clinical documentation. Part D plans must respond to standard coverage determinations within 72 hours.

How to Verify Your Specific Plan's Metformin Coverage

Every Part D plan publishes its formulary online. Here is how to check your plan's metformin coverage and copay:

Step 1: Go to Medicare.gov's Plan Finder tool. Enter your ZIP code and select your current plan (or compare plans during Open Enrollment, October 15 through December 7).

Step 2: Search the plan's formulary for "metformin." The tool shows the covered formulations, tier placement, quantity limits, and any prior authorization or step therapy requirements.

Step 3: Check the plan's Evidence of Coverage (EOC) document for the copay or coinsurance amount at each tier during each phase of coverage (deductible, initial coverage, coverage gap).

Step 4: If your plan has a deductible, note whether Tier 1 generics are exempt. Many Part D plans waive the deductible for preferred generics, meaning you pay the copay from day one rather than paying full price until the deductible is met.

For 2025 and 2026, the standard Part D deductible is $590 [8]. Plans that exempt Tier 1 generics from the deductible (the majority do) let you start paying your low copay for metformin immediately in January.

If you are switching plans during Annual Enrollment or considering a Medicare Advantage plan with drug coverage, verify that your preferred pharmacy is in the plan's network. Out-of-network pharmacy fills can cost substantially more, even for inexpensive generics.

Extended-Release Metformin: Coverage Differences Worth Knowing

Metformin extended-release (ER) is prescribed for patients who experience gastrointestinal side effects with immediate-release formulations. GI symptoms (diarrhea, nausea, abdominal cramping) are the most common reason patients discontinue metformin, affecting roughly 20-30% of patients started on immediate-release tablets according to a Cochrane systematic review [18].

Part D coverage of ER formulations is nearly universal, but the tier placement may differ. Some plans place metformin ER on Tier 2 rather than Tier 1, increasing the copay by $3 to $10. A small number of plans apply step therapy, requiring a trial of immediate-release metformin before covering ER.

The clinical rationale for ER over IR is well-established. A randomized crossover study published in Diabetes, Obesity and Metabolism (N=532) found that metformin ER produced comparable A1c reductions to immediate-release (mean difference 0.04%, not statistically significant) with 50% fewer GI adverse events [19]. If your prescriber recommends ER and your plan requires step therapy, the prescriber can submit a formulary exception request with documentation of GI intolerance.

Metformin ER is typically dosed once daily (1,000 mg to 2,000 mg with the evening meal), compared to twice or three-times daily dosing for immediate-release. This simplification may improve adherence, which the WHO has identified as one of the primary challenges in chronic disease management [20].